

FOR IMMEDIATE RELEASE

Company Name Kyowa Kirin Co., Ltd.
Representative Masashi Miyamoto, President and CEO
(Code No. 4151, Prime Market of TSE)
Inquiries Hiroki Nakamura, Executive Vice President,
Corporate Communications Department
Media Contact: +81-3-5205-7205
Investor Contact: +81-3-5205-7206

Notice Regarding Changes of Representative Directors

Tokyo, Japan, October 31, 2024 - Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto) hereby announced that at the Board of Directors meeting held today, Kyowa Kirin agreed on changes of its Representative Directors, as follows. The changes will be formally approved at the Ordinary General Meeting of Shareholders and the Board of Directors meeting to be held in March 2025.

1. Changes of the Representative Directors

1-1. Nominee for a new Chairman and Representative Director

Name	New Position	Current Position
Masashi Miyamoto	Representative Director Chairman and Chief Executive Officer (CEO)	Representative Director President and Chief Executive Officer (CEO)

1-2. Nominee for a new Representative Director

Name	New Position	Current Position
Abdul Mullick	Representative Director President and Chief Operating Officer (COO)	Managing Executive Officer and Chief International Business Officer (CIBO)

1-3. Retiring Representative Director

Name	Current Position
Yutaka Osawa	Representative Director Executive Vice President and Chief Compliance Officer (CCO)

2. Reason for change

Kyowa Kirin has focused on three Core strategies aimed: "Providing pharmaceuticals for unmet medical needs," "Address patient-centric healthcare needs," and " Retain the trust of society." to realize its 2030 vision.

Additionally, in 2024, we established the "Story for Vision 2030" with enhanced clarity on how Kyowa Kirin aims to realize its 2030 vision. We specified the disease areas and modalities we will focus on for drug discovery and clarified the selection of business models -- distinguishing between assets we

will develop and market ourselves and those we will develop and market with partners. Based on this strategy, we will maximize the creation of “life-changing value”.

At this time, Kyowa Kirin will step into a new stage of its transformation into a Japan-based global specialty pharmaceutical company by making enhancements to the management team at the global level which we believe will help us achieve further heights. In the new structure, we have decided to establish a Chief Operating Officer (COO), and to adopt a dual structure of CEO and COO. The Chairman & CEO will lead discussions on the Kyowa Kirin's direction and overall strategy, while maintaining relationships with stakeholders. The President & COO will oversee the execution of all business operations at the global level, enhancing collaboration across regions and functions, and will promptly and steadily advance the management strategy.

Abdul Mullick, the nominee for President & COO, has extensive knowledge and experiences in the global deployment of pharmaceuticals including rare diseases. Throughout his six-year career with Kyowa Kirin, he has led the growth of the business, including global products. By transforming the business in the EMEA and APAC regions, he has reshaped the organization into its ideal form through effective dialogue. This demonstrates his exceptional management skills across the business, organization, and employees. Considering these aspects and following thorough discussions within the Nomination & Remuneration Consultative Committee, he has been nominated as the most suitable nominee for the position of Kyowa Kirin's top leader.

Furthermore, he has been residing in Tokyo since 2023 and is engaged in his current role based in Japan. He will continue to lead the management of Kyowa Kirin in the same manner moving forward.

3. Personal history of Nominee of new Representative Director

Name: Abdul Mullick

Place of Birth: The United Kingdom

Date of Birth: May 14, 1967

Degree: PhD- Molecular Biology, University of Bristol, UK

BSc- Molecular Biology, Kingston University, UK

Career History:

January 1999	Sanofi-Aventis Pharma AG; France, Germany, UK Global Marketing Director–Diabetes, European Marketing Director–Diabetes, Sales & Marketing Manager–Diabetes
--------------	--

January 2005	Novartis Pharma AG; Switzerland Senior Global Brand Director-Diabetes
--------------	--

December 2007	Genzyme Corporation; 2007: EMEA Business Unit Head, Endocrinology; UK 2009: Vice President Commercial Operations, Renal & Endocrinology–Japan, Asia-Pac, Australia & China; Singapore 2011: Vice President, Head of Global Marketing, Rare Diseases; USA 2013: Vice President, GM, Endocrinology & Cardiology, Rare Diseases; USA
September 2014	Vifor Pharma Ltd; Switzerland Executive Vice President, Head of Global Marketing
March 2018	Kyowa Kirin Group March 2018: Executive Vice President, Rare Diseases Head, Kyowa Kirin International plc; UK April 2019: President, Kyowa Kirin International plc; UK January 2023: Managing Executive Officer, Vice Chief International Business Officer, Kyowa Kirin Co., Ltd.; Tokyo, Japan March 2023: Managing Executive Officer, Chief International Business Officer, Kyowa Kirin Co., Ltd.; Tokyo, Japan April 2024: Managing Executive Officer, Chief International Business Officer (CIBO), Kyowa Kirin Co., Ltd.; Tokyo, Japan (to present)

Number of shares of the company held by the candidate: 0 shares (As of October 31, 2024)

4. Effective date

The official appointments are subject to the approval at the Ordinary General Meeting of Shareholders and the Board of Directors meeting to be held in March 2025.

End